PT-141 Research: What the Studies Actually Show

PT-141, known in the scientific literature as bremelanotide, is a cyclic heptapeptide — seven amino acid residues, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, closed into a macrocycle by a lactam bridge between the side chains of the aspartate and lysine residues. It is a close chemical relative of Melanotan II, the compound it was derived from; the two share the same ring and differ at the C-terminus, where PT-141 carries a free carboxylic acid in place of an amide. Both descend from α-melanocyte-stimulating hormone (α-MSH) and preserve its His-Phe-Arg-Trp core recognition motif, with the natural L-phenylalanine replaced by its D-enantiomer. This article covers how that structure engages the melanocortin receptors MC4R, MC3R and MC1R, what cell assays and rodent genetics have established about the signaling that follows, and where the evidence runs out. For background on how ring closure and residue substitution change a peptide’s behaviour at a receptor, see our primer on peptide structure and signaling.

Research-use-only context. This article summarizes published third-party scientific literature — the large majority of it conducted in cultured cells or animal models. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. American Peptides products are sold strictly for in vitro laboratory research and are not for human or veterinary use.

What PT-141 is

The melanocortins were first described in 1916, and a century of work has resolved five receptors for them — MC1R through MC5R — all class A G-protein-coupled receptors. A 2022 Biomolecules review by Yuan and Tao notes that MC3R and MC4R are expressed primarily in the central nervous system, which is why they are called the neural melanocortin receptors, while MC1R was characterized on melanocytes; the endogenous ligands are the MSH peptides and adrenocorticotropin on the agonist side and agouti-related peptide on the antagonist side.⁷

MC4R itself was cloned in 1993 by Gantz and colleagues in the Journal of Biological Chemistry. By Northern blot and in situ hybridization, expression was primarily in the brain and notably absent from the adrenal cortex, melanocytes and placenta. Agonist stimulation of transfected COS-1 and L-cells raised intracellular cyclic 3′,5′-adenosine monophosphate, and the profile of responses to different melanocortins distinguished this receptor from the three described before it.¹ That work fixed two facts: MC4R is a brain receptor, and its canonical readout is cyclic AMP.

PT-141 is not a selective ligand within that family. Its parent scaffold, MT-II, is described in the medicinal-chemistry literature as a potent and unselective agonist across the human melanocortin receptors,³ and PT-141 carries the same macrocycle. The 2022 review lists bremelanotide among the small number of melanocortin ligands that reached pharmaceutical status.⁷

What cell and tissue studies report

The lactam ring is what sets affinity

The clearest structure–activity evidence bearing on PT-141 concerns the ring it shares with MT-II. In a 2022 Journal of Medicinal Chemistry study, Tomassi and colleagues replaced the lactam cyclization of MT-II with xylene-derived thioethers and ran the products through binding assays at the human melanocortin receptors. Affinities spanned the low nanomolar to the sub-micromolar range, correlating with which linker was used, and one analogue — unlike the unselective parent peptide — showed marked functional selectivity for hMC1R, which enhanced-sampling molecular dynamics attributed to the conformational constraint the new bridge imposed.³ The ring is not incidental packaging: changing it moves affinity across roughly three orders of magnitude and can turn an unselective agonist into a subtype-selective one.

Receptor structure, and a metal ion in the binding site

In 2020, Yu and colleagues reported in Science the structure of the antagonist SHU9119 bound to human MC4R at 2.8-angstrom resolution. Two findings constrain how any melanocortin agonist result should be read. First, Ca²⁺ was identified as a cofactor complexed with residues contributed by both the receptor and the peptide ligand; extracellular Ca²⁺ increased the affinity of the endogenous agonist α-MSH at MC4R by 37-fold and its potency by 600-fold. Second, the crystallized construct coupled to the ion channel Kir7.1 while lacking cyclic AMP stimulation — a G-protein-independent signaling modality. The authors also characterize MC4R as a structurally divergent GPCR, more similar to lipidic GPCRs than to the homologous peptidic ones.⁴

What agonist binding does to the receptor

The activation mechanism was resolved the following year. Heyder and colleagues, in Cell Research, reported cryogenic electron microscopy structures of MC4R–Gs-protein complexes with two peptide agonists: NDP-α-MSH, a high-affinity linear variant of the endogenous agonist, at 2.9 Å, and setmelanotide, a cyclic agonist, at 2.6 Å. Combined with signaling data from structure-derived MC4R mutants, the structures located the agonist-induced origin of transmembrane helix 6-regulated activation, and identified helix 3 as the locus of ligand-specific interactions and calcium as a ligand-adaptable cofactor. That helix-3 interplay propagates to the receptor–Gs interface at intracellular loop 2, which regulates the coupling profile of what the authors call a promiscuous receptor; setmelanotide showed biased signaling toward Gq/11.⁵ Setmelanotide is, like PT-141, a cyclized melanocortin agonist, but the literature does not appear to contain a structure of PT-141 bound to any melanocortin receptor.

A cell assay using bremelanotide itself

One recent in vitro study used the compound directly: Suzuki, Kitanaka and Okada, in Anticancer Research in 2024, examined bremelanotide in human glioblastoma cell lines, measuring survivin expression and cell viability. Bremelanotide reduced survivin expression and induced cell death at concentrations that were not toxic to normal human cells, and both effects were cancelled in the presence of an antagonist of melanocortin receptors 3 and 4. Forced over-expression of survivin prevented the cell death.⁶ The antagonist result is the useful part, placing the effect downstream of MC3R and MC4R rather than off-target. It is also a transformed cell-line model, and nothing in it addresses central melanocortin signaling.

What animal models report

The animal literature here is a genetics literature, and it is where receptor attribution was established. In 1997, Huszar and colleagues reported in Cell that inactivating the melanocortin-4 receptor by gene targeting in mice produced a maturity-onset obesity syndrome, measured as excess body weight accompanied by hyperphagia, hyperinsulinemia and hyperglycemia. The syndrome recapitulated features of the agouti obesity syndrome, and the authors’ interpretation was that agouti protein produces obesity primarily through chronic antagonism of MC4R.² The design is why it remains the reference point for this field: the finding came from removing the receptor, not from adding a ligand.

The second study is the one most relevant to PT-141’s chemistry. Marsh and colleagues, in Nature Genetics in 1999, measured food intake in Mc4r-deficient mice and reported that these animals did not respond to the appetite-suppressing actions of MTII, the MSH-like agonist that shares PT-141’s macrocyclic scaffold — evidence, the authors argue, that α-MSH suppresses feeding primarily by acting through Mc4r. The same paper reported that obese Mc4r-null mice did not respond significantly to leptin’s inhibitory effect on feeding while non-obese Mc4r-null mice did, indicating that Mc4r is not an exclusive target of leptin action, while responses to neuropeptide Y, peptide YY, urocortin and corticotropin-releasing factor were preserved, placing those neuromodulators independent of or downstream of Mc4r.⁸

What that result shows is narrow: one measured output of the parent macrocycle requires MC4R, by loss of function in mice, read out as food intake. It is not a measurement of PT-141, and not a circuit mechanism.

Where the human evidence stops

The structural biologists on this receptor are the first to call the account unfinished. The Science group identified a signaling modality that operates without G proteins at all — a revision to the receptor’s own signaling map arriving nearly three decades after it was cloned.⁴ The Cell Research group presents its structures as a basis for future compound design, not a settled mechanism.⁵ The 2022 review frames the neural melanocortin receptors as an emerging target and catalogues ligands rather than outcomes.⁷

On regulatory status, two statements need to be kept separate. The compound was evaluated in regulated trials and a related pharmaceutical exists. That history does not transfer to a research reagent: PT-141 supplied as a laboratory chemical is not approved by the FDA for any use, is investigational in every context described in this article, and has no human data of its own; as a research material it is characterized by identity, purity, net peptide content and stability, and nothing else.

None of the mechanistic work summarized above was conducted in humans: the receptor structures are of purified recombinant protein, the affinity and cyclic AMP measurements come from transfected cell lines, and the receptor-attribution experiments are mouse genetics. The hypothalamic circuitry this receptor sits in is characterized almost entirely in rodents, and human melanocortin pharmacology at the level of circuit mechanism has not been established.

What is not established

• PT-141’s own affinity and potency profile across MC1R, MC3R, MC4R and MC5R. The published affinity series centre on MT-II and SHU9119 analogues rather than on PT-141 itself.³
• Which G-protein coupling PT-141 favours at MC4R, and whether it shows the Gq/11 bias reported for another cyclic melanocortin agonist.⁵
• Whether the Kir7.1-coupled, cyclic-AMP-independent modality at MC4R is engaged by PT-141 at all.⁴
• How much of any melanocortin agonist’s measured potency is a property of the assay buffer rather than the ligand, given the 600-fold calcium shift.⁴
• Whether the MC3R/MC4R-dependent pathway seen in glioblastoma lines reflects receptor behaviour in non-transformed tissue.⁶
• Whether the mouse receptor-attribution findings describe human MC4R circuits, and what sustained receptor engagement does to MC4R expression and desensitization in any species.^2,8

Frequently Asked Questions

What kind of molecule is PT-141?

A cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, closed by a lactam bridge between the aspartate and lysine side chains. It is built on the His-Phe-Arg-Trp core of α-MSH with a D-phenylalanine substitution, and is a close relative of Melanotan II, from which it differs at the C-terminus.

Which receptors does PT-141 act on?

The melanocortin receptors. MC3R and MC4R are the two expressed primarily in the central nervous system; MC1R was characterized on melanocytes.⁷ PT-141’s parent scaffold MT-II is described as unselective across the human subtypes,³ and MC4R’s canonical readout is cyclic AMP,¹ with a G-protein-independent, Kir7.1-coupled modality also reported.⁴

What does the MC4R knockout literature show?

Two things. Inactivating the receptor in mice produced a maturity-onset obesity syndrome with hyperphagia, hyperinsulinemia and hyperglycemia.² And Mc4r-deficient mice did not respond to the appetite-suppressing actions of MTII, the agonist sharing PT-141’s macrocycle, indicating that this output of the scaffold requires MC4R.⁸

Is PT-141 approved by the FDA?

No. PT-141 supplied as a research chemical is not approved by the FDA for any use. The compound was evaluated in regulated trials and a related pharmaceutical exists, but that regulatory history does not extend to a laboratory reagent. American Peptides supplies PT-141 strictly for in vitro research.

Citations

1. Gantz I, Miwa H, Konda Y, et al. “Molecular cloning, expression, and gene localization of a fourth melanocortin receptor.” J Biol Chem. 1993;268(20):15174–15179. PubMed: PMID 8392067
2. Huszar D, Lynch CA, Fairchild-Huntress V, et al. “Targeted disruption of the melanocortin-4 receptor results in obesity in mice.” Cell. 1997;88(1):131–141. PubMed: PMID 9019399
3. Tomassi S, Dimmito MP, Cai M, et al. “CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.” J Med Chem. 2022;65(5):4007–4017. PubMed: PMID 35188390
4. Yu J, Gimenez LE, Hernandez CC, et al. “Determination of the melanocortin-4 receptor structure identifies Ca²⁺ as a cofactor for ligand binding.” Science. 2020;368(6489):428–433. PubMed: PMID 32327598
5. Heyder NA, Kleinau G, Speck D, et al. “Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide.” Cell Res. 2021;31(11):1176–1189. PubMed: PMID 34561620
6. Suzuki S, Kitanaka C, Okada M. “Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.” Anticancer Res. 2024;44(9):3875–3883. PubMed: PMID 39197897
7. Yuan XC, Tao YX. “Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.” Biomolecules. 2022;12(10):1407. PubMed: PMID 36291616
8. Marsh DJ, Hollopeter G, Huszar D, et al. “Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides.” Nat Genet. 1999;21(1):119–122. PubMed: PMID 9916804

Related reading

• What Is a Peptide? A Researcher’s Primer on Structure and Signaling
• Receptor Pathways: A Researcher’s Primer
• Amino Acid Signaling and Receptor Biology: A Research Primer
• How Signaling Peptides Work: A Complete Science Explainer

This article is for laboratory research reference only. American Peptides products are sold strictly for in vitro research. Not for human consumption.

---

Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.